

AZD-8835

Chemical Properties


CAS No. : 1620576-64-8

Formula: C₂₂H₃₁N₉O₃

Molecular Weight: 469.54

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	AZD-8835 is a mixed inhibitor of PI3K α/δ (IC ₅₀ : 6.2/5.7 nM), also with selectivity against PI3K β/γ (IC ₅₀ : 431/90 nM).
Targets(IC ₅₀)	PI3K
In vitro	AZD8835 is a potent inhibitor of PI3K α (wild type, E545K and H1047R mutations) and PI3K δ with excellent selectivity vs. PI3K β , PI3K γ and an excellent general kinase selectivity. AZD8835 is a potent inhibitor of p-Akt in cells sensitive to PI3K α inhibition (IC ₅₀ =0.057 μ M in PIK3CA mutant human breast ductal carcinoma BT474 cell line) and in cells sensitive to PI3K δ inhibition (IC ₅₀ =0.049 μ M in JeKo-1 B cell line), but not to cells sensitive to PI3K β inhibition (IC ₅₀ =3.5 μ M in PTEN null breast adenocarcinoma MDA-MB-468 cell line) or PI3K γ inhibition (IC ₅₀ =0.53 μ M in monocytic RAW264 cell line)[2].
In vivo	AZD8835 has antitumor efficacy in corresponding breast cancer xenograft models when dosed continuously and displays high metabolic stability and suitable physical properties for oral administration[1][2].
Cell Research	BT474, MCF7, or T47D cells are seeded in 384-well plates at a density of 500 to 2,000 cells per well and incubated overnight. Cells are dosed with compound(s) and cell confluency is measured at 4-hour intervals over several days.(Only for Reference)

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: < 1 mg/mL (insoluble or slightly soluble), DMSO: 86 mg/mL (183.16 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

A DRUG SCREENING EXPERT

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1297 mL	10.6487 mL	21.2974 mL
5 mM	0.4259 mL	2.1297 mL	4.2595 mL
10 mM	0.213 mL	1.0649 mL	2.1297 mL
50 mM	0.0426 mL	0.213 mL	0.4259 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Hudson K, et al. Mol Cancer Ther. 2016, 15(5):877-89.

Bernard Barlaam, et al. Bioorganic & Medicinal Chemistry Letters. 2015, 25(22):5155-5162.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481